论文部分内容阅读
目的探讨氟哌噻吨美利曲辛片与尼莫地平治疗偏头痛患者的临床效果。方法选取2014年1月至2015年6月黑龙江省医院神经内科收治的82例偏头痛患者作为研究对象,按照随机数字表法将其分为A组与B组,每组41例。A组患者采用氟哌噻吨美利曲辛片进行治疗,B组患者给予尼莫地平片,比较两组患者临床疗效、治疗前后头痛症状改善情况及不良反应发生情况。结果 A组患者治疗的总有效率明显高于B组,差异有统计学意义(P<0.05);治疗后,A组患者的头痛发作次数、疼痛视觉模拟量表(VAS)评分均显著低于B组,持续时间明显短于B组,差异均有统计学意义(均P<0.05)。结论氟哌噻吨美利曲辛片用于治疗偏头痛的疗效显著优于尼莫地平,能够有效改善患者症状,且不良反应较少,是一种相对安全有效的药物。
Objective To investigate the clinical effects of flupentixol and melitracen tablets and nimodipine in patients with migraine. Methods A total of 82 patients with migraine who were admitted to Department of Neurology, Heilongjiang Provincial Hospital from January 2014 to June 2015 were selected as research objects. According to the random number table, they were divided into group A and group B, 41 cases in each group. Patients in group A were treated with flupentixol and melitracen tablets. Patients in group B were given nimodipine tablets. The clinical efficacy, the improvement of headache symptoms and the incidence of adverse reactions before and after treatment were compared between the two groups. Results The total effective rate of treatment in group A was significantly higher than that in group B, the difference was statistically significant (P <0.05). After treatment, the number of headache and visual analog scale (VAS) in group A were significantly lower than that of group B B group, the duration was significantly shorter than the B group, the differences were statistically significant (P <0.05). Conclusion The efficacy of flupentixol and melitracen tablet in the treatment of migraine is significantly better than nimodipine, which can effectively improve the symptoms of patients with less adverse reactions. It is a relatively safe and effective drug.